rs111033205
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP4
The NM_000441.2(SLC26A4):c.85G>C(p.Glu29Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000153 in 1,557,858 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000441.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000105 AC: 16AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000926 AC: 15AN: 162000Hom.: 0 AF XY: 0.0000572 AC XY: 5AN XY: 87366
GnomAD4 exome AF: 0.000158 AC: 222AN: 1405620Hom.: 0 Cov.: 30 AF XY: 0.000163 AC XY: 113AN XY: 694860
GnomAD4 genome AF: 0.000105 AC: 16AN: 152238Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74378
ClinVar
Submissions by phenotype
not provided Pathogenic:7
This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 29 of the SLC26A4 protein (p.Glu29Gln). This variant is present in population databases (rs111033205, gnomAD 0.03%). This missense change has been observed in individuals with SLC26A4-related conditions (PMID: 11317356, 15355436, 16570074, 20597900, 25394566). ClinVar contains an entry for this variant (Variation ID: 4839). An algorithm developed to predict the effect of missense changes on protein structure and function outputs the following: PolyPhen-2: "Benign". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Experimental studies have shown that this missense change affects SLC26A4 function (PMID: 19017801). This variant disrupts the p.Glu29 amino acid residue in SLC26A4. Other variant(s) that disrupt this residue have been observed in individuals with SLC26A4-related conditions (PMID: 22285650, 25372295), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. -
- -
- -
Published functional studies demonstrate a damaging effect due to reduced iodide transport activity (PMID: 19017801); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 14679580, 29372807, 24224479, 17503324, 16950989, 18285825, 15099345, 15355436, 16570074, 20597900, 23336812, 31589614, 34426522, 34170635, 33199029, 31541171, 36499699, 11317356, 19017801, 36555390, 36833263, 25394566, 25372295, 12642503, 22285650) -
PM2_supporting, PM3_very_strong, PS3_supporting -
- -
- -
Autosomal recessive nonsyndromic hearing loss 4 Pathogenic:6
- -
- -
- -
- -
- -
- -
Pendred syndrome Pathogenic:3
- -
- -
- -
Wolff-Parkinson-White pattern Pathogenic:1
This variant was identified in an individual with Wolff-Parkinson-White syndrome -
SLC26A4-related disorder Pathogenic:1
Across a selection of the available literature, the SLC26A4 c.85G>C (p.Glu29Gln) missense variant has been reported in at least nine studies in which it was identified in a total of 18 individuals, including in a compound heterozygous state in 14 individuals, in a heterozygous state in three individuals, in a double heterozygous state in one individual and in one individual with unknown zygosity. Affected individuals were diagnosed with either Pendred syndrome, an autosomal recessive form of deafness, or enlarged vestibular aqueduct or Mondini dysplasia (Campbell et al. 2001; Prasad et al. 2004; Blons et al. 2004; Alberts et al. 2006; Yang et al. 2007; Pera et al. 2008; Pourova et al. 2010; Rendtorff et al. 2013; Ladous et al. 2014). The p.Glu29Gln variant was found to segregate in at least one study (Yang et al. 2007). The variant was absent from 469 controls and is reported at a frequency of 0.000229 in the European (non-Finnish) population of the Genome Aggregation Database. Functional studies using fluorimetric measurements showed that the p.Glu29Gln variant protein has reduced chloride/iodide transport (Pera et al. 2008). Based on the collective evidence, the p.Glu29Gln variant is classified as pathogenic for SLC26A4-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. -
Rare genetic deafness Pathogenic:1
The p.Glu29Gln variant in SLC26A4 has been identified in multiple individuals wi th hearing loss and temporal bone abnormalities including over 15 probands who w ere compound heterozygous with another pathogenic variant in SLC26A4, and it has segregated in three affected siblings (Albert 2006, Campbell 2001, Gardner 2006 , Ladsous 2014, Pera 2008, Pourova 2010, Rendtorff 2013, LMM unpublished data). Functional studies have demonstrated that this variant impacts the protein func tion (Pera 2008). In summary, this variant meets our criteria to be classified as pathogenic for DFNB4 nonsyndromic hearing loss or Pendred syndrome in an auto somal recessive manner. -
Pendred syndrome;C3538946:Autosomal recessive nonsyndromic hearing loss 4 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at